Navigation Links
ResearchMoz: Biosimilar/Follow-on Biologics Market Report & Forecast: A Focus on the US (2011-2020)
Date:12/12/2011

ALBANY, New York, December 12, 2011 /PRNewswire/ --

New Report Added in ResearchMoz Reports Database Biosimilar/Follow-on Biologics Market Report & Forecast: A Focus on the US (2011-2020) Published by IMARC.

With sales worth US$ 57 Million in 2010, biosimilars are still far from their billion dollar sales potential that most analysts believe they will generate. This market, however, unlike small molecule generics, is expected to be more akin to a marathon than a sprint. IMARC Group, one of the world's leading research and advisory firms, in its new report "Biosimilar/Follow-on Biologics Market Report & Forecast: A Focus on the US (2011-2020)" finds that biosimilars in the US will soon represent a multi-billion dollar market as they would be posing stiff competition to as many as twenty biological molecules during 2011-2020.

Browse the full Report:  http://www.researchmoz.com/biosimilar-follow-on-biologics-market-report-and-forecast-a-focus-on-the-us-2011-2020-report.html 


Findings from the report suggest that the historical performance of Omnitrope cannot be taken as a benchmark to gauge the potential of pipeline biosimilars as market acceptance for each biosimilar class is expected to vary significantly from one another. The report expects that the competition between branded biological drugs and their biosimilar counterparts would be more of a brand-brand competition than a brand-generic competition. The high costs involved in the development and launch of biosimilars are expected to limit the number of players in this market. As a result, erosions in price and volume caused by biosimilars are likely to be lower compared to those created by small molecule generics.


IMARC's new report entitled "Biosimilar/Follow-on Biologics Market Report & Forecast: A Focus on the US (2011-2020)" provides an analytical and statistical insight into the US biosimilar market. The study, that has been undertaken using desk-based as well as qualitative primary research, provides and draws upon analysis of six aspects of the US biosimilar market.


Key Aspects Analyzed:


Evaluating the Current Market Landscape of Biosimilars:

  • Identification of currently marketed biosimilars and their historical performance
  • Identifying the reasons for the slow uptake of currently marketed biosimilars
  • Analyzing historical data to formulate conclusions on the future growth and market trends of biosimilars

Evaluating the Extent of Price, Sales and Volume Erosions Caused by Biosimilars:

  • Analyzing historical time series data on price, volume and sales erosion in the US & Europe
  • Analyzing previous models and assumptions on price and volume erosion caused by biosimilars
  • Evaluating and comparing price and volume erosion created by biosimilars vis-a-vis by small molecule generics
  • Evaluating and comparing price, volume and sales erosion by biosimilars across various biological classes

Evaluating the Market Potential of Biosimilars Across Various Molecules: Molecules Covered: Somatropin (Genotropin/Humatrope/Other HGH), Epoetin Alfa (Epogen/Eprex), Filgrastim (Neupogen), Pegfilgrastim (Neulasta), Insulin Lispro (Humalog), Insulin Glargine (Lantus), Insulin Detemir (Levemir), Interferon Beta-1A (Avonex), Interferon Beta-1A (Rebif), Interferon Beta-1B (Betaferon), Bevacizumab (Avastin), Trastuzumab (Herceptin), Rituximab (Mabthera/Rituxan), Cetuximab (Erbitux), Etanercept (Enbrel), Infliximab (Remicade), Adalimumab (Humira), Ranibizumab (Lucentis), Omalizumab (Xolair) and Natalizumab (Tysabri).


Focus of the Analysis for Each Molecule:

  • Historical background and overview
  • Historical brand sales
  • Patent position
  • Competing products
  • Biosimilars in pipeline
  • Brand and biosimilar sales forecasts

Evaluating the Sales of Biosimilars across Various Indications:


Indications Covered: Immunology & Inflammation, Diabetes, Oncology, Blood Disorders and Growth Deficiency


Focus of the Analysis for Each Indication:

  • Historical brand sales
  • Brand and biosimilar sales forecasts
  • Indication wise breakup of molecules

Evaluating the Biosimilar Competitive Landscape:

  • Identifying branded biological manufacturers that expect the highest amount of erosion from biosimilars
  • Identifying biosimilar manufacturers and their pipelines

Understanding the Current Legislation on Biosimilars:

  • An insight into the Biologics Price Competition and Innovation Act
  • An insight into the key biosimilar issues that still remain unaddressed
  • Interchangeability and Substitutability
  • Data Exclusivity
  • Statutory provisions for dealing with patent litigations


Browse All  Biotechnology Market  Research Reports & Industry Analysis

Related Reports

Generic Growth Strategies - Manufacturers to Increase Focus on Super Generics and Biosimilars to Drive Revenues

Cancer Supportive Care Products Market to 2016 - Market is Expected to Decline after 2014 Due to Generic Erosion and Entry of Biosimilars

Biosimilars Approval Pathways in the US and Europe - Development and Approval of Biosimilar mABs May Face Tough Regulatory Environment

Biotechnology Industry 2010 Yearbook - Top Biologics, Biosimilars, Licensing and Financing, Mergers and Acquisitions

Oxygen Concentrator Market

Application Server Market

Digital Dentistry Market

About Us

ResearchMoz is the one stop online destination to find and buy market research reports. We fulfill all your research needs spanning across industry verticals with our huge collection of market research reports. We provide our services to all sizes of organizations and across all industry verticals and markets. Our Research Coordinators have in-depth knowledge of reports as well as publishers and will assist you in making an informed decision by giving you unbiased and deep insights on which reports will satisfy your needs at the best price.

Contact
M/s Sheela
90 Sate Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: +1-866-997-4948
Email:  sales@researchmoz.com
http://www.researchmoz.com/
Baby Food Market
http://www.findmarketresearch.org/



'/>"/>
SOURCE ResearchMoz
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. ORENCIA(R) (abatacept) Supplemental Biologics License Application for Juvenile Idiopathic Arthritis Accepted by FDA for Filing and Review
2. Insmed Launches National Awareness Campaign Surrounding Follow-On Biologics
3. Insmed Provides Update on Follow-On Biologics and IPLEX(TM) Programs
4. CTI to Meet With the FDA to Discuss Filing of a Supplemental Biologics License Application for Zevalin(R)
5. Insmed CEO to Present at Congressional Briefing on Follow-On Biologics
6. Interface Biologics Anti-Thrombic Additives Show Equivalent Efficacy to Commercial Heparinized Coatings
7. FDA Grants Priority Review of a Supplemental Biologics License Application for Cinryze(TM) C1 Inhibitor (Human) as Treatment for Acute Attacks of Hereditary Angioedema (HAE)
8. Bone Biologics Announces Significant Milestone for Spinal Fusion Surgery Using Recombinant Protein and Demineralized Bone Matrix
9. Isolagen, Inc. Submits Biologics License Application for the Treatment of Wrinkles to the U.S. Food and Drug Administration
10. Food and Drug Administration Accepts Isolagens Biologics License Application for Full Review
11. CMC ICOS Biologics and Implicit Bioscience Ltd Announce IC14 Antibody Manufacturing Agreement and Patent License
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... , Dec. 8, 2016 Global ... report on the global interventional radiology market analyzes ... The report comprises an elaborate executive summary, including ... various segments and sub-segments. The research is ... research formed the bulk of our research efforts ...
(Date:12/8/2016)... -- Eli Lilly and Company (NYSE: LLY ) ... trial at the 9 th Clinical Trials on ... not meet the primary endpoint in the EXPEDITION3 clinical ... mild dementia due to Alzheimer,s disease (AD), and Lilly ... treatment of mild dementia due to AD. ...
(Date:12/8/2016)... Dec. 8, 2016 Bodycad announced it ... improving the accuracy, reproducibility and speed for 3D ... and small bone orthopaedic applications. These patents are ... personalized orthopaedic restorations based on each patient,s distinct ... the company harnesses the world,s first suite of ...
Breaking Medicine Technology:
(Date:12/9/2016)... ... December 09, 2016 , ... The American Speech-Language-Hearing Association ... a critical part of public access to hearing aid technology. , ASHA emphasized ... week that, starting immediately, it would no longer enforce the requirement that ...
(Date:12/9/2016)... ... December 09, 2016 , ... "I have gout, and I wanted to ... recipe, which is meant to relieve gout and pain caused by varicose veins. I ... boost every time. It relieved what VA doctors called the worst sinusitis case they'd ...
(Date:12/9/2016)... ... December 09, 2016 , ... Mediaplanet today announces distribution of the latest edition ... to sign up as an organ donor for the 123,000 people in the United ... donor can save up to 8 saves through organ donation and enhance many others ...
(Date:12/9/2016)... ... December 09, 2016 , ... The Pennsylvania Athletic ... (PCN) during the summer of 2016. The program was made possible by a ... States Department of Health and Human Services Administration. The broadcast, Use Your ...
(Date:12/8/2016)... ... December 08, 2016 , ... ... LLC, announced the first national #QuackGivesBack campaign which supported local breast cancer organizations ... first franchise-wide Quack Gives Back initiative, and we’re very pleased with ...
Breaking Medicine News(10 mins):